pramipexole + ropinirole

The combination of **pramipexole** and **ropinirole** refers to the two primary non-ergot-derived dopamine agonists used in the management of Parkinson's disease (PD). In clinical trial contexts such as the **PD MED** study, these agents are frequently grouped together as the representative treatment arm for the dopamine agonist class. Both molecules function as synthetic agonists with high affinity for the **D2** and **D3** dopamine receptor subtypes in the striatum, mimicking the effect of endogenous dopamine to improve motor symptoms. They are utilized as initial monotherapy to delay the requirement for levodopa or as adjuvant therapy to levodopa to reduce motor fluctuations ("off" periods) and lower the required levodopa dose. Clinical use of these agents is associated with specific adverse events, most notably **impulse control disorders** (e.g., compulsive gambling, shopping, or hypersexuality), peripheral edema, and sudden onset of sleep. Unlike older ergot-derived agonists like pergolide, pramipexole and ropinirole carry a significantly lower risk of cardiac valvulopathy.

Brand names

MirapexRequipSifrolAdartrel

Other names

Non-ergot dopamine agonistspramipexole + ropirinole